Anlon Healthcare shines on developing two new anti-malarial products
Anlon Healthcare is currently trading at Rs 142.93, up by 8.50 points or 6.32% from its previous closing of Rs 134.43 on the BSE.
The scrip opened at Rs 136.70 and has touched a high and low of Rs 147.80 and Rs 132.00 respectively. So far 171319 shares were traded on the counter.
The BSE group 'B' stock of face value Rs 10 has touched a 52-week high of Rs 147.80 on 22-Sep-2025 and a 52-week low of Rs 86.98 on 05-Sep-2025.
Last one week high and low of the scrip stood at Rs 147.80 and Rs 106.30 respectively. The current market cap of the company is Rs 769.53 crore.
The promoters holding in the company stood at 52.68%, while Institutions and Non-Institutions held 18.77% and 28.55% respectively.
Anlon Healthcare has successfully developed two new anti-malarial products, Artemether and Lumefantrine. The company is expected to launch both products by November 2025. This development is in line with its strategy to expand the product portfolio and cater to the evolving needs of its clientele.
Anlon Healthcare is a chemical manufacturing company engaged in manufacturing of pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs), which are supplied to customers both in India and international markets.
